Mangoceuticals Granted 180‑Day Nasdaq Extension to Regain $1 Bid

What Happened Mangoceuticals, Inc. (MGRX) announced on Aug. 4, 2026 that Nasdaq has granted a second 180‑calendar‑day compliance period—until Feb. 1, 2027—for the company to regain compliance with the $1.00 minimum bid price requirement. The company previously received a deficiency notice on Feb. 4, 2026 after its common stock closed below $1.00 for 30 consecutive business days. The Nasdaq Staff said the company meets all other initial listing requirements (including market value of publicly held shares) except the bid price.

Key Details

• Nasdaq Listing Rule cited: 5550(a)(2) (minimum bid price) and initial compliance rule 5810(c)(3)(A).
• Initial deficiency notice: Feb. 4, 2026; initial compliance period expired Aug. 3, 2026.
• Second Notice received: Aug. 4, 2026, extending compliance deadline to Feb. 1, 2027.
• Nasdaq’s extension was based on the company meeting other listing standards and the company’s stated intention to cure the deficiency, including the possibility of a reverse stock split.
• The Second Notice does not affect current listing or trading; a press release was filed as Exhibit 99.1.

Why It Matters Nasdaq’s extension gives shareholders and the company more time to resolve the sub‑$1 share price issue without immediate delisting. However, the company remains out of compliance with the minimum bid price rule, and failure to regain a $1 closing bid by Feb. 1, 2027 could lead to delisting proceedings. Investors should watch the company’s closing bid price, any announcements about corporate actions (such as a reverse stock split), and further Nasdaq communications.